Analysts focus on three programs in big year for Bristol Myers

FierceBiotechAstraZeneca's camizestrant ambitions stumble as FDA panel rejects novel oral SERD proposal

Endpoints NewsHouse panel calls to ban China trial data from FDA drug trial applications

Endpoints NewsCourt dismisses part of Lilly lawsuit against Empower, some claims can proceed

Endpoints NewsSupreme Court questions how far generics makers can go with 'skinny label' drugs

Merck KGaAMerck KGaA taps into Remepy’s Hybrid Drug platform - The Pharma Letter

GE HealthCareGE HealthCare’s stock plunges 13% as supply chain costs bite - Medical Device Network

BioPharma DiveMerck still sees ‘compelling’ outlook for Terns leukemia drug

Merck & Co.Merck & Co lifts outlook as Keytruda growth offsets acquisition hit - The Pharma Letter

CellProteostasis sustains T cell differentiation potential and tumor-infiltrating lymphocyte function

CellDifferential inhibition of Morbillivirus and Henipavirus polymerases by ERDRP-0519 and structure-guided inhibitor optimization

BioWorldAppointments and advancements for April 30, 2026

BioWorldFinancings for April 30, 2026